Hours later, the Massachusetts Attorney General issued a temporary restraining order preventing the NIH from immediately cutting billions in the grants it issues to scientists and

The National Institutes of Health said it will cap indirect grant funds, threatening billions of dollars in health systems' grant revenue.

“If small biotech companies like ours are forced to scale back or shut down, it will not just be a loss for scientific innovation but for the patients whose lives depend on these breakthroughs,” Dr. Choukri Ben Mamoun, a professor of medicine and founder of Curatix and Virtus Therapeutics, wrote in an email to the News.